The increased expression of cluster of differentiation (CD)47 has been identified in a number of different tumor types and is recognized as an adverse prognostic factor that indicates an increased risk of mortality in patients. The binding of CD47 to signal regulatory protein α (SIRPα) inhibits the macrophage phagocytosis of tumor cells by triggering an inhibitory 'do not eat me' signal. This is one of the mechanisms used by tumor cells to evade immune surveillance. In the present study, CD47 levels and macrophage infiltration were assessed in patients with esophageal squamous cell cancer (ESCC). CD47-overexpressing ESCC cell lines were selected and human M2 macrophage phagocytic activity was measured. The results revealed that CD47 is highly expressed and macrophages are markedly infiltrated in cancerous tissue compared with non-cancerous tissue. High CD47 expression was detected in ESCC cell lines and the results of a phagocytosis assay indicated that human M2 macrophages phagocytized tumor cells in a dose-dependent manner following the blocking of CD47-SIRPα signaling by anti-CD47 antibodies. The results of the present study therefore support the use of anti-CD47 immunotherapy to treat patients with ESCC.
Introduction
Esophageal cancer (EC) is a common cause of cancerassociated mortality worldwide (1) . In total, ~0.5 million individuals are diagnosed with EC every year in China (2) . There are two major histological subtypes of EC: Esophageal squamous cell cancer (ESCC), which is the most common type worldwide, including in China, and esophageal adenocarcinoma (EAC), which is the fastest increasing subtype of EC being diagnosed in Western countries (3, 4) . Currently, the standard treatment of EC is surgery combined with chemotherapy and/or radiation, depending on the stage at which the cancer is diagnosed (5) . However, the 5-year survival rate of patients with advanced forms of EC remains poor (5-30%) (6, 7) .
The effectiveness of immunotherapy has been clinically proven and may therefore be developed as a novel method of treating cancer (8) (9) (10) . Treatments that block checkpoint inhibitors, including cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1) and programmed death-ligand 1 (PD-L1), have been approved by the US Food and Drug Administration to treat melanoma, non-small-cell lung cancer, head and neck cancer, renal cancer and non-Hodgkin's lymphoma (8) . Compared with standard therapies, remarkable efficacy has been achieved following the use of checkpoint inhibitors; however, a number of patients with melanoma exhibit no response or resistance to immune checkpoint blockades (11) (12) (13) . Therefore, it is necessary to identify novel targets and strategies to improve current therapies for cancer.
Among the potential novel targets that have been identified, cluster of differentiation (CD) 47 is of particular interest. CD47 is a widely expressed transmembrane protein belonging to the immunoglobulin superfamily (14) . The binding of CD47 to signal regulatory protein α (SIRPα), which is expressed on myeloid cells, induces an inhibitory 'do not eat me' signal that attenuates macrophage phagocytic activity (15) . CD47 is highly expressed in many different types of cancer, including breast, ovarian, colon and bladder cancer, glioblastoma and various hematological types of cancer (16) (17) (18) (19) (20) (21) (22) . Furthermore, high CD47 expression in tumor cells is associated with poor clinical outcomes (20, 22, 23) . It has been suggested that tumors evade macrophage phagocytosis by activating the inhibitory signal via the ligation of SIRPα expressed on phagocytes with CD47 (which is highly expressed on cancer cells) (24) . Tumors utilize this mechanism to escape immune surveillance.
In the present study, CD47 expression and macrophage infiltration were determined in patients with ESCC. It was assessed whether blocking CD47 signaling with anti-CD47 antibodies enhances macrophage phagocytosis of human ESCC cells in vitro. To the best of our knowledge, the present study is the first to characterize the phagocytic activity of human macrophages against ESCC cells. These results provide rationale and support for the use of anti-CD47 immunotherapy to treat patients with ESCC.
Materials and methods
Patient samples. ESCC biopsies were collected from 14 patients (6 male and 8 female; mean age, 62.7±7.3 years old), who underwent potential curative surgery at the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) between July 2015 and June 2016 ( Table I ). All tissue samples were collected prior to chemotherapy or radiotherapy. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University and written informed consent was obtained from each patient. Surgeries were classified as curative as there was no evidence of residual tumors and resected margins were microscopically free of tumors following surgery (R0) (25) . Non-cancerous (normal) tissues obtained from ESCC were obtained from the Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University (Henan, China). Samples were divided and either immediately frozen in liquid nitrogen and stored at -80˚C for RNA isolation or fixed in 10% neutral-buffered formalin for 24 h (22-25˚C) prior to immunohistochemical (IHC) analysis.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from ESCC tissue using TRIzol reagent (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and reverse transcribed following the manufacturer's protocol (cat. no. RR047A; Takara Biotechnology Co., Ltd., Dalian, China). Subsequently, qPCR was performed using the SYBR-Green Master mix (cat. no. 4472908; Thermo Fisher Scientific, Inc.) on the 7500 Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Thermocycling conditions were as follows; holding on at 50˚C for 2 min; pre-denaturation at 95˚C for 2 min; followed by 15 sec at 95˚C then 1 min at 60˚C for 40 cycles; melt curve was at 95˚C for 15 sec, 1 min at 60˚C, 15 sec at 95˚C and 15 sec at 60˚C. The following primers were used: Human CD47 forward, 5'-GGC AAT GAC GAA GGA GGT TA-3' and reverse, 5'-ATC CGG TGG TAT GGA TGA GA-3'; and human β-actin forward, 5'-GGG AAA TCG TGC GTG ACA TT-3' and reverse, 5'-GGA AGG AAG GCT GGA AGA GT-3'. RNA levels were normalized to β-actin expression and relative expression was calculated using the change-in-quantification (2 -ΔΔCq ) method (26) . IHC analysis. IHC analysis was performed to evaluate the expression of CD47 and CD68 in tumor tissues. Specimens were fixed in 10% neutral-buffered formalin for 24 h (22-25˚C), embedded in paraffin and cut into 4-µm-thick sections. Sections were deparaffinized with xylene and rehydrated in a descending series of ethanol. Non-specific staining was blocked by incubating slides with a 5% bovine serum albumin buffer (cat. no. A8020; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for 30 min at room temperature. Tissue sections were subsequently incubated with primary antibodies against human CD47 (1:100; cat. no. ab134484; Abcam, Cambridge, MA, USA) and human CD68 (1:100; cat. no. ab955; Abcam) at 4˚C overnight. CD68 is a glycoprotein that binds to low-density lipoprotein and is expressed on monocytes and macrophages. It is a well-known cell surface marker for macrophages (27) . Slides were then incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-mouse IgG (1:5,000; cat. no. SA00001-1; Wuhan Sanying Biotechnology, Wuhan, China). Chromagens were detected using 3,3'-diaminobenzidine.
Alternatively, certain sections were stained with hematoxylin and eosin (H&E) in the absence of primary antibodies separately. Slides were dehydrated and mounted for observation using a light microscope (magnification, x200 and x400). Flow cytometry. Flow cytometry was performed to measure the number of different cell types and protein expression in ESCC cell lines. Cells were washed with cold PBS and incubated with fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD47 primary antibodies as part of the mouse anti-human CD47-FITC detection kit (1:100; cat. no. 11-0479-42; eBioscience; Thermo Fisher Scientific, Inc.) or a corresponding FITC-conjugated mouse immunoglobulin (Ig) G1k isotype control as part of the mouse IgG1k-FITC isotype control detection kit (1:100; cat no. 14-4714-82; eBioscience; Thermo Fisher Scientific, Inc.) for 15 min at room temperature (22-25˚C). Following washing with PBS, cells were analyzed using a LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using FlowJo ® software (version 10; FlowJo LLC, Ashland, OR, USA).
In vitro phagocytosis assay. ESCC cells were pHrodo™ Red-labeled (cat. no. P36600; Molecular Probes; Thermo Fisher Scientific, Inc.) and incubated with human M2 macrophages at 22-25˚C (in a 2:1 target:effector cell ratio) according to the manufacturer's protocol in the presence of 20 µg/ml mouse IgG1 isotype (control; 1:100; cat. no. BE0083; BioXcell, West Lebanon, NH, USA) or mouse anti-human CD47 antibodies (1:100; cat. no. BE0019-1; BioXcell) for 2 h. Cells were subsequently analyzed using immunofluorescence microscopy (magnification, x100 and x400) to determine the phagocytic index (number of tumor cells ingested/100 macrophages by counting). In the dose-response study, the anti-hCD47 antibody concentration was serially diluted from 300 to 0.03 µg/ml by a dilution factor of 3.
Statistical analysis. Data are presented as the mean ± standard error of the mean. All data were analyzed using SPSS (version 13; SPSS, Inc., Chicago, IL, USA). One-way analysis of variance was used to detect differences among groups. If a significant difference was identified, the Fisher least significant difference test was used to detect specific differences between the study groups. All experiments were repeated ≥3 times. P<0.05 was considered to indicate a statistically significant difference.
Results
Patients with ESCC express high levels of CD47. Cancerous tissue and corresponding non-cancerous tissue biopsies were collected from 14 patients with ESCC and CD47 mRNA expression was measured. The results revealed that CD47 mRNA expression was significantly higher in cancerous tissue compared with non-cancerous tissue (Fig. 1A) . IHC analysis revealed extensive anti-CD47 staining on the surface of tumor cells, supporting the results of RT-qPCR ( Fig. 1B) . Additionally, high anti-CD47 staining was observed on the surface of stromal and infiltrated cells, including the presence of fibroblasts and macrophages in the tumor region. In contrast, minimal anti-CD47 staining was observed in the corresponding non-cancerous tissue.
Macrophages are highly infiltrated in patients with ESCC.
High expression of surface CD47 helps tumor cells evade immune surveillance by binding to SIRPα expressed on the cell surface of phagocytes (24) . To evaluate the status of macrophage infiltration in patients with ESCC, anti-CD68 IHC staining was conducted in cancerous and corresponding non-cancerous tissue. Anti-CD68 staining was detected in the tumor tissue in the infiltrated macrophages and in the extracellular matrix of tumor cells ( Fig. 2A) . Contrastingly, minimal anti-CD68 staining was observed in the non-cancerous tissue. H&E staining determined whether immune cell infiltration had occurred. Heavy immune cell infiltration was observed in the cancerous tissue but not in the non-cancerous tissue (Fig. 2B ).
CD47 expression was identified in certain cell lines derived from patients with ESCC.
Increased CD47 expression has been reported in various tumor cell lines (28) . To evaluate whether CD47 is also highly expressed in ESCC, CD47 expression in 5 different ESCC lines were examined using flow cytometry. The results revealed that the TE-8 cell line expressed high levels of CD47 whereas the KYSE-30 and KYSE-270 cell lines expressed limited amounts of CD47 (Fig. 3A) . Levels of CD47 in the TE-1 and TE-10 cell lines were undetectable (data not shown). The expression of CD47 mRNA in ESCC-derived cell lines was also investigated. The results were consistent with those for RNA expression; it was demonstrated that the TE-8 cell line expressed the highest level of CD47 mRNA (Fig. 3B) . KYSE-30 expressed significantly lower mRNA levels compared with TE-8 and KYSE-270 expressed significantly lower levels of CD47 compared with TE-8 and KYSE-30. Table I . Demographic information of patients with ESCC included in the study (n=14). The TNM stage and pathology stage of ESCC were defined following the American Joint Committee on Cancer cancer staging protocol.
Patient ID T3N0M0 T3N0M0 T3N1M0 T3N2M0 T2N0M0 T3N0M0 T1bN0M0 T1aN0M0 T3N2M0 T1bN1M0 T2N1M0 T1bN1M0 T3N2M0 T3N0M0   Pathological stage   IIB   IIB   IIIA   IIIB   IIA   IIB   IA   IB   IIIB   IIB   IIA   IIB   IIIB   IIB   TNM human ESCC cells (KYSE-270, KYSE-30, and TE-8; Fig. 4A ). Anti-CD47 (20 µg/ml) treatment significantly increased the M2 macrophage ingestion of TE-8 cancer cells exhibiting high CD47 expression, compared with KYSE-30 cancer cells exhibiting lower CD47 expression and the IgG1 control group (Fig. 4B) . The IgG1 control treatment group exhibited minimal macrophage phagocytic activity and was significantly reduced compared with the TE-8 and KYSE-30 groups. It was also observed that anti-CD47 blocking promoted macrophage phagocytosis of TE-8 cancer cells in a dose-dependent manner (Fig. 4C ).
Discussion
Out of all the solid tumors, the mortality rate of patients with ESCC is particularly high due to its aggressive dissemination and the absence of clear clinical symptoms (1, 29) . Although multidisciplinary approaches, including surgery, radiotherapy and chemotherapy have markedly improved patient outcomes, novel therapeutic strategies are required to treat patients with ESCC due to poor survival rates (5) . Checkpoint inhibitor immunotherapy has been evaluated for the treatment of ESCC (9,10). Doi et al (9) demonstrated that pembrolizumab (anti-hPD-1 antibody) treatment in patients with PD-L1-positive ESCC led to a partial response (PR) rate of 29.4%; however no patients exhibited a complete response (CR). Kudo et al (10) also reported that treatment with nivolumab (another anti-hPD-1 antibody) in patients with advanced ESCC and not preselected by PD-L1 status resulted in a PR rate of 15.6% and a CR rate of 1.6%, with a median overall survival (OS) time of 12.1 months. The results of these studies indicate that anti-PD-1 antibody therapy is a potential treatment for patients with ESCC but suggest that anti-PD-1 alone is not enough to promote tumor regression in the majority of patients with cancer. To produce a robust therapeutic immune response, a combination of treatments may be required.
CD47 is recognized as a checkpoint for the innate immune response and delivers an inhibitory signal when it binds with SIRPα expressed on phagocytes (30) (31) (32) . Anti-CD47 treat- [30] [31] [32] . Anti-CD47 treat--32). Anti-CD47 treat-32). Anti-CD47 treat-). Anti-CD47 treatment enhances the efficacy of anti-PD-1 and anti-CTLA-4 in pre-clinical models of ESCC (33) . CD47 expression has been used as a novel prognostic marker in patients with ESCC (34) and a study by Yang et al (35) demonstrated that CD47 is a potential target in the treatment of laryngeal squamous cell carcinoma (LSCC). In the present study, patients did not take any anti-cancer medication and samples were collected prior to chemo-or radiotherapy, therefore, the expression of CD47 was unaffected. It has been demonstrated that cancerous tissues expressed significantly higher CD47 levels than non-cancerous tissues in patients with ESCC. IHC staining confirmed that CD47 was highly expressed in the tumor cells of patients with ESCC. These results are consistent with previously published data in which CD47 levels in tumor tissues were significantly higher than those in non-tumor tissues in patients with ESCC or LSCC (34, 35) . In addition, increased levels of tumor tissue infiltration by macrophages were observed in the current study. Macrophages are one of the major cell types that express the CD47 receptor SIRPα. Therefore, the increased CD47 expression on tumor cells and infiltrated macrophages identified in the present study may further enhance the inhibitory 'do not eat me' signal, which contributes to the tumor cell evasion of immune surveillance.
In tumor tissue, macrophages may be characterized as M1 or M2. M1 macrophages exhibit anti-tumor activity and M2 macrophages exhibit pro-tumor activity (36) . It has been demonstrated that blocking CD47-SIRPα signaling with anti-CD47 antibodies enhances phagocytic activity from M1 and M2 macrophages and promotes tumor regression (37) . Furthermore, blocking CD47-SIRPα signaling enhances the macrophage phagocytosis of various tumor cells in vitro (18, 22, 38) . In the present study, it was demonstrated that human M2 macrophages phagocytized CD47-high ESCC cells in a dose-dependent manner following the addition of anti-CD47 antibodies to the cell culture. To the best of our knowledge, the present study is the first to demonstrate macrophage phagocytic activity against EC cells in vitro. These results support the use of CD47 as a target for the treatment of ESCC.
In conclusion, the present study demonstrates high CD47 expression and macrophage infiltration in patients with ESCC, which allows tumor cells to hijack CD47-SIRPα inhibitory signaling and avoid attack by immune cells. Anti-CD47 antibodies may enhance macrophage phagocytic activity against ESCC cells in vitro. The present study provides a rationale for the potential use of anti-CD47 antibodies in novel therapeutic strategies to treat ESCC.
